注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
Achilles Therapeutics PLC是一家总部位于英国的临床阶段免疫肿瘤生物制药公司。该公司开发转化性精准T细胞疗法来治疗多种类型的实体瘤。该公司主导产品是针对克隆性癌症新抗原的精准肿瘤衍生T细胞疗法。其管线包括Chiron:晚期非小细胞肺癌、Thetis:黑色素瘤(单一疗法)、Thetis:黑色素瘤(PD-1联合疗法)和其他适应症。该公司专注于通过其在肿瘤进化领域的工作推进癌症治疗。其平台能够识别在癌症发展早期形成的突变,这些突变会产生由患者所有癌细胞表达但健康组织中不存在的抗原。该公司将这类实体瘤靶标称为克隆新抗原。为了识别患者体内的克隆新抗原,该公司开发了一个名为PELEUS的生物信息学平台。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Carsten Boess | 54 | 2020 | Independent Non-Executive Director |
Edwin Moses | 67 | 2018 | Independent Chairman of the Board |
Iraj Ali | 45 | 2016 | CEO & Director |
Michael F. Giordano | 66 | 2018 | Independent Non-Executive Director |
Julie O’Neill | 58 | 2021 | Non-Executive Director |
Elizabeth M. Jaffee | - | 2020 | Member of Scientific Advisory Board |
Christopher A. Klebanoff | - | 2020 | Member of Scientific Advisory Board |
Scott Joseph Antonia | - | 2020 | Member of Scientific Advisory Board |
Markwin Velders | - | 2021 | Member of Scientific Advisory Board |
Cassian Yee | - | 2022 | Member of Scientific Advisory Board |
Bernhard R. M. Ehmer | 69 | 2022 | Non-Executive Director |
Alena Gros | - | 2022 | Member of Scientific Advisory Board |
Ben Creelan | - | 2022 | Member of Scientific Advisory Board |
Julie O'Neill | 58 | - | Non-Executive Director |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核